ClinicalTrials.gg
RecruitingNCT07577843DUET ENCORE-CDUpdated Nov 3, 2026

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of JNJ-78934804 and Guselkumab in Crohn Disease, sponsored by Janssen Research & Development, LLC. Recruiting at 287 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 3, 2026First sites in 7 new countriesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Crohn Disease by Johnson & Johnson — 16 open to participants now, 23 under way, 10 of them phase 3. Crohn Disease · Johnson & Johnson.

Planned enrollment
12th of 40
460 · median 189
Started
2026
with 8 others
Phase 3
23 of 63
4 open now
Primary completion
2028-06
later than 9 of 22 live
Registered
58th of 63
by date

Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 12th largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 in phase 3, reaches primary completion later than 9 of the 22 other live ones, and was the 58th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

16 of the 63 studies in Crohn Disease by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Crohn Disease by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intestine).

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
  • Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score >= 220 but less than or equal to (\<=) 450 and either: a. Mean daily stool frequency (SF) count >= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score >= 2.0, based on the unweighted CDAI component of abdominal pain (AP)
  • Have moderately to severely active ileal and/or colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria
  • Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies

Exclusion criteria

Exclusion criteria:

  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, ulcerative colitis (UC) or clinical findings highly suggestive of UC
  • Complications of CD such as symptomatic bowel strictures or stenoses, or any other manifestation that may require intestinal surgery while enrolled in the study
  • Presence of draining (that is, functioning) stoma or ostomy
  • Has a history of short bowel syndrome, is missing greater than (>) 2 of the 5 ileocolonic segments, or has any other medical condition that could preclude or confound the ability to use efficacy assessment tools (such as CDAI) to assess response to study intervention
  • Currently has or is suspected of having an abscess
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    JNJ-78934804

    Participants will receive JNJ-78934804 induction dose, at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804

  • Active comparator
    Guselkumab

    Participants will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the LTE phase.

    Drug: JNJ-78934804 · Drug: Guselkumab

Interventions

  • JNJ-78934804 will be administered subcutaneously.

    Also known as: JNJ-4804

  • Guselkumab will be administered subcutaneously.

    Also known as: TREMFYA

06

What researchers measure

Primary outcomes

  1. Co-Primary: Percentage of Participants with Clinical Remission at Week 48

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than (\<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 48

  2. Co-Primary: Percentage of Participants with Endoscopic Remission at Week 48

    Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of less than or equal to (\<=) 4 with at least a 2-point reduction from baseline and no subscore greater than (\>) 1 in any individual component. The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants with Deep Remission at Week 48

    Deep remission (composite endpoint) is defined as achieving both clinical remission and endoscopic remission at Week 48 at the participant level. Clinical remission is defined as a CDAI score of \<150 and Endoscopic remission is defined as a SES-CD score of \<= 4 with at least a 2-point reduction from baseline and no subscore \>1 in any individual component. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 48

  2. Percentage of Participants with Corticosteroid-Free (90-Day) Clinical Remission at Week 48

    Corticosteroid-free (90-day) clinical remission at Week 48 is defined as clinical remission at Week 48 and not receiving corticosteroids for at least 90 days prior to Week 48. Clinical remission is defined as a CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 48

  3. Percentage of Participants with Corticosteroid-Free (90-day) PRO-2 Remission at Week 48

    Corticosteroid-free (90-day) patient-reported outcome(s) (PRO-2) remission at Week 48 is defined as an abdominal plan (AP) mean daily score less than or equal to (\<=) 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline, and not receiving corticosteroids for at least 90 days prior to Week 48.

    Time frame: At Week 48

  4. Percentage of Participants with Sustained Clinical Remission

    Sustained clinical remission is defined as clinical remission at Week 12 and Week 48. Clinical remission is defined as CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Weeks 12 and 48

  5. Percentage of Participants with Histologic-Endoscopic Remission at Week 48

    Composite endpoint defined as achieving both histologic remission (defined as a Robarts Histopathology Index score less than or equal to \[\<=\] 3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0) and endoscopic remission at the participant level.

    Time frame: At Week 48

  6. Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48

    IBDQ response at Week 48 is defined as an improvement of at least 16 points in the IBDQ total score from baseline at Week 48. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate disease-specific health related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, AP), systemic function (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week 48

  7. Percentage of Participants with Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Mental Component Summary Score (MCS) Response at Week 48

    PROMIS-29 MCS response at Week 48 is defined as an improvement of at least 7 points in PROMIS-29 MCS score from baseline at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). PROMIS-29 also includes an overall average pain intensity 0-10 numeric rating scale. The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.

    Time frame: At Week 48

  8. Percentage of Participants with Clinical Remission at Week 12

    Clinical remission at Week 12 is defined as CDAI score \<150 at Week 12. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 12

  9. Percentage of Participants with Endoscopic Response at Week 12

    Endoscopic response at Week 12 is defined as greater than (\>) 50 percent (%) improvement from baseline in SES-CD score at Week 12 or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 12

  10. Percentage of Participants with Clinical Response at Week 4

    Clinical response at week 4 is defined as \>=100-point reduction from baseline in CDAI score at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 4

  11. Percentage of Participants with Clinical Remission at Week 4

    Clinical remission at Week 4 is defined as CDAI score \<150 at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 4

  12. Number of Participants with Adverse Events (AE) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to approximately 3 years

07

Study locations

285 of 287 sites recruiting

Showing the first 100 of 287 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 24 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
May 22, 2026
Primary completionEst.
Jun 12, 2028
CompletionEst.
Jul 12, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
171 sites added, 26 sites removed — first sites in Austria, Greece, Hungary, Italy, Romania and 2 more
All 7 countries

Austria, Greece, Hungary, Italy, Romania, Switzerland, United Kingdom

. Royal Victoria Infirmary is now Active, not recruiting
Show 171 added (15 France, 13 Germany, 12 China, 12 Poland, 12 United Kingdom, 11 Italy, 10 United States, 9 Brazil, 8 Japan, 7 Australia, 6 Romania, 5 Hungary, 4 Austria, 4 Belgium, 4 Czechia, 4 Norway, 4 Spain, 3 Argentina, 3 Greece, 3 India, 3 Portugal, 3 South Korea, 3 Taiwan, 3 Turkey (Türkiye), 2 Canada, 2 Netherlands, 2 Switzerland, 2 Israel, 1 Slovakia, 1 Malaysia)
  • GIA Metairie · Metairie, United States
  • GIA Kansas City · Lee's Summit, United States
  • Sanatorio Duarte Quiroz · Córdoba, Argentina
  • Hospital Provincial del Centenario · Rosario, Argentina
  • SA Gastrointestinal Services IBD SA · Kurralta Park, Australia
  • Macquarie University · Macquarie University, Australia
  • Fiona Stanley Hospital · Murdoch, Australia
  • Kepler Universitatsklinikum GmbH · Linz, Austria
  • Krankenhaus der Barmherzigen Brüder · Vienna, Austria
  • Klinikum Wels Grieskirchen · Wels, Austria
  • O L V Ziekenhuis · Aalst, Belgium
  • Cliniques Universitaires Saint Luc · Brussels, Belgium
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu · Botucatu, Brazil
  • CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda · Jaú, Brazil
  • Galileo Medical Research Ltda · Juiz de Fora, Brazil
  • Complexo Hospitalar de Niteroi · Niterói, Brazil
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto · Ribeirão Preto, Brazil
  • Solare Trials · São Paulo, Brazil
  • Nova Scotia Health Victoria General Site · Halifax, Canada
  • Toronto Digestive Disease Associates Inc · Vaughan, Canada
  • The second Xiangya Hospital of Central South University · Changsha, China
  • The First People's Hospital of Foshan · Foshan, China
  • The First Affiliated Hospital of Anhui Medical University · Hefei, China
  • Lanzhou University Second Hospital · Lanzhou, China
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
  • The Central Hospital of Wuhan · Wuhan, China
  • Wuxi People s Hospital · Wuxi, China
  • Zhongshan Hospital, Xiamen University · Xiamen, China
  • Oblastni nemocnice Kladno a.s. · Kladno, Czechia
  • Fakultni Nemocnice Ostrava · Ostrava-Poruba, Czechia
  • …and 141 more on the registry record
Show 26 removed
  • IBD SA · Kurralta Park, Australia
  • Michigan Center of Medical Research · Farmington Hills, United States
  • GEDYT · AAI, Argentina
  • The Melbourne Gut Clinic Epworth Hospital · East Melbourne, Australia
  • SA Gastrointestinal Services IBD SA · Kurralta Park, Australia
  • Macquarie University · Macquarie University, Australia
  • John Hunter Hospital · New Lambton Heights, Australia
  • Cliniques Universitaires Saint Luc · Brussels, Belgium
  • Ghent University Hospital · Ghent, Belgium
  • Fakultni Nemocnice Ostrava · Ostrava-Poruba, Czechia
  • CHRU de Nancy - Hopitaux de Brabois · Vandœuvre-lès-Nancy, France
  • Gastroenterologische Spezialpraxis - Berlin-Karlshorst · Karlshorst, Germany
  • Sushruta Multispecialty Hospital and Research Centre · Hubballi, India
  • P D Hinduja National Hospital and Medical Research Center · Mumbai, India
  • Wolfson Medical Center · Holon, Israel
  • Shaare Zedek Medical Center · Jerusalem, Israel
  • Ospedale Sacro Cuore Negrar-Verona · Negrar-Verona, Italy
  • Azienda Ospedaliera San Camillo-Forlanini · Roma, Italy
  • Fondazione Policlinico Universitario A Gemelli IRCCS · Roma, Italy
  • Fatebenefratelli Isola Tiberina - Gemelli Isola · Roma, Italy
  • Hyogo Medical University Hospital · Nishinomiya Shi, Japan
  • Hospital Sultanah Nur Zahirah · Kuala, Malaysia
  • Akershus Universitetssykehus · Lorenskog, Norway
  • Samsung Medical Center · Gangnam Gu, South Korea
  • Izmir Sehir Hastanesi · Izmir, Turkey (Türkiye)
  • Izmir Katip Celebi University Ataturk Training and Research Hospital · Turkey, Turkey (Türkiye)
across 2 updates, Oct 14, 2026 – Nov 3, 2026
Secondary outcomes
2 added, 1 description edited
What changed in the outcomes
  • AddedPercentage of Participants with Clinical Response at Week 4Time frame: At Week 4
  • AddedPercentage of Participants with Clinical Remission at Week 4Time frame: At Week 4
  • DescriptionPercentage of Participants with Histologic-Endoscopic Remission at Week 48: how it is measured was reworded
Oct 14, 2026
Show all 2 updates
  1. Nov 3, 2026
    60 sites added, 25 sites removed. Royal Victoria Infirmary is now Active, not recruiting
    Show 60 added (8 United States, 5 France, 5 Germany, 4 Australia, 4 China, 4 Italy, 4 United Kingdom, 3 Brazil, 3 Japan, 2 Belgium, 2 Czechia, 2 India, 2 Israel, 2 Poland, 2 Turkey (Türkiye), 1 Argentina, 1 Austria, 1 Greece, 1 Malaysia, 1 Norway, 1 Romania, 1 South Korea, 1 Switzerland)
    • Mayo Clinic · Scottsdale, United States
    • GIA Sun City · Sun City, United States
    • Endoscopic Research Inc · Orlando, United States
    • GIA Rochester · Rochester, United States
    • Michigan Center of Medical Research · Farmington Hill, United States
    • Palmetto Primary and Specialty Care Physicians, Charleston · Summerville, United States
    • GIA Webster · Webster, United States
    • GIA Richmond · Richmond, United States
    • GEDYT · Famailla, Argentina
    • SA Gastrointestinal Services IBD SA · Kurraba Point, Australia
    • Macquarie University · Macquarie Island, Australia
    • John Hunter Hospital · New Lambton, Australia
    • The Melbourne Gut Clinic Epworth Hospital · West Melbourne, Australia
    • LKH - Universitätsklinikum der PMU Salzburg · Salzburg, Austria
    • Cliniques Universitaires Saint Luc · Brussel (Bruxelles), Belgium
    • Ghent University Hospital · Gent (Ghent), Belgium
    • L2IP Instituto de Pesquisas Clinicas · Brasília, Brazil
    • Liga Norte Riograndense Contra O Cancer · Natal, Brazil
    • Clinica Ibis Medicina Ltda · Salvador, Brazil
    • West China Hospital Si Chuan University · Chengdu, China
    • Jiangsu Province Hospital · Nanjing, China
    • Ruijin Hospital Shanghai Jiao Tong University · Shanghai, China
    • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Fakultni Nemocnice Ostrava · Ostrava, Czechia
    • IKEM · Prague, Czechia
    • CHU Amiens · Amiens, France
    • APHP - Hopital Henri Mondor · Créteil, France
    • Clinique Ambroise Pare · Neuilly-sur-Seine, France
    • Centre Hospitalier Lyon Sud · Oullins, France
    • CHRU de Nancy - Hopitaux de Brabois · Vanduvre-lès-Nancy, France
    • …and 30 more on the registry record
    Show 25 removed
    • Michigan Center of Medical Research · Farmington Hills, United States
    • GEDYT · AAI, Argentina
    • The Melbourne Gut Clinic Epworth Hospital · East Melbourne, Australia
    • SA Gastrointestinal Services IBD SA · Kurralta Park, Australia
    • Macquarie University · Macquarie University, Australia
    • John Hunter Hospital · New Lambton Heights, Australia
    • Cliniques Universitaires Saint Luc · Brussels, Belgium
    • Ghent University Hospital · Ghent, Belgium
    • Fakultni Nemocnice Ostrava · Ostrava-Poruba, Czechia
    • CHRU de Nancy - Hopitaux de Brabois · Vandœuvre-lès-Nancy, France
    • Gastroenterologische Spezialpraxis - Berlin-Karlshorst · Karlshorst, Germany
    • Sushruta Multispecialty Hospital and Research Centre · Hubballi, India
    • P D Hinduja National Hospital and Medical Research Center · Mumbai, India
    • Wolfson Medical Center · Holon, Israel
    • Shaare Zedek Medical Center · Jerusalem, Israel
    • Ospedale Sacro Cuore Negrar-Verona · Negrar-Verona, Italy
    • Azienda Ospedaliera San Camillo-Forlanini · Roma, Italy
    • Fondazione Policlinico Universitario A Gemelli IRCCS · Roma, Italy
    • Fatebenefratelli Isola Tiberina - Gemelli Isola · Roma, Italy
    • Hyogo Medical University Hospital · Nishinomiya Shi, Japan
    • Hospital Sultanah Nur Zahirah · Kuala, Malaysia
    • Akershus Universitetssykehus · Lorenskog, Norway
    • Samsung Medical Center · Gangnam Gu, South Korea
    • Izmir Sehir Hastanesi · Izmir, Turkey (Türkiye)
    • Izmir Katip Celebi University Ataturk Training and Research Hospital · Turkey, Turkey (Türkiye)
    + 1 other change: verification date
  2. Oct 14, 2026
    111 sites added, 1 site removed — first sites in Austria, Greece, Hungary, Italy, Romania and 2 more
    All 7 countries

    Austria, Greece, Hungary, Italy, Romania, Switzerland, United Kingdom

    Show 111 added (10 France, 10 Poland, 8 China, 8 Germany, 8 United Kingdom, 7 Italy, 6 Brazil, 5 Hungary, 5 Japan, 5 Romania, 4 Spain, 3 Australia, 3 Austria, 3 Norway, 3 Portugal, 3 Taiwan, 2 United States, 2 Argentina, 2 Belgium, 2 Canada, 2 Czechia, 2 Greece, 2 Netherlands, 2 South Korea, 1 India, 1 Slovakia, 1 Switzerland, 1 Turkey (Türkiye))
    • GIA Metairie · Metairie, United States
    • GIA Kansas City · Lee's Summit, United States
    • Sanatorio Duarte Quiroz · Córdoba, Argentina
    • Hospital Provincial del Centenario · Rosario, Argentina
    • SA Gastrointestinal Services IBD SA · Kurralta Park, Australia
    • Macquarie University · Macquarie University, Australia
    • Fiona Stanley Hospital · Murdoch, Australia
    • Kepler Universitatsklinikum GmbH · Linz, Austria
    • Krankenhaus der Barmherzigen Brüder · Vienna, Austria
    • Klinikum Wels Grieskirchen · Wels, Austria
    • O L V Ziekenhuis · Aalst, Belgium
    • Cliniques Universitaires Saint Luc · Brussels, Belgium
    • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu · Botucatu, Brazil
    • CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda · Jaú, Brazil
    • Galileo Medical Research Ltda · Juiz de Fora, Brazil
    • Complexo Hospitalar de Niteroi · Niterói, Brazil
    • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto · Ribeirão Preto, Brazil
    • Solare Trials · São Paulo, Brazil
    • Nova Scotia Health Victoria General Site · Halifax, Canada
    • Toronto Digestive Disease Associates Inc · Vaughan, Canada
    • The second Xiangya Hospital of Central South University · Changsha, China
    • The First People's Hospital of Foshan · Foshan, China
    • The First Affiliated Hospital of Anhui Medical University · Hefei, China
    • Lanzhou University Second Hospital · Lanzhou, China
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    • The Central Hospital of Wuhan · Wuhan, China
    • Wuxi People s Hospital · Wuxi, China
    • Zhongshan Hospital, Xiamen University · Xiamen, China
    • Oblastni nemocnice Kladno a.s. · Kladno, Czechia
    • Fakultni Nemocnice Ostrava · Ostrava-Poruba, Czechia
    • …and 81 more on the registry record
    Show 1 removed
    • IBD SA · Kurralta Park, Australia
    Secondary outcomes 2 added, 1 description edited
    What changed in the outcomes
    • AddedPercentage of Participants with Clinical Response at Week 4Time frame: At Week 4
    • AddedPercentage of Participants with Clinical Remission at Week 4Time frame: At Week 4
    • DescriptionPercentage of Participants with Histologic-Endoscopic Remission at Week 48: how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577843
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 22, 2026
Primary completion
Jun 12, 2028 (estimated)
Completion
Jul 12, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-78934804

Start the discussion